To produce a prolonged decrease m blood pressure, we have developed a nonpathogenic adeno-associated viral vector (AAV) with the antIsense DNA for AT1-R AAV has many advantages over other viral vectors AAV does not stimulate mflammallon or immune reaction AAV enters nondtvlchng cells and does not replicate Therefore, it IS an appropriate choice for gene therapy Recombinant AAV was prepared with a cassette contaumg a cytomegalovtrus promoter and the cDNA for the AT, receptor inserted m the annsense dire&on The cassette was packaged ohgonucleotides, directed to either AT,-R mRNA or to anglotensmogen mRNA, slgmfscantly reduce blood pressure m hypertensive animals with a single mJection mto the bram I-3 Although the adn-nmstration of antisense m the brain proved that antlsense can reduce high blood pressure of neurogemc orlgm, it obviously 1s not an acceptable route for treatment of human hypertension To demonstrate that antisense acts via a systemic route of delivery, we have shown that antisense delivered mtravenously4 or mtra-arterially5 can also reduce blood pressure m hypertensive rats. Antisense AT1 mRNA significantly decreased the blood pressure m 2&idney, 1 clip rats, m which circulating remn-Ang levels are high 4 Anglotensmogen mRNA-directed antIsense ohgonucleotide, in a hposome carrier inJected mtravenously m SHR, also decreased hypertension 5 The uptake of antisense was predommantly m the hver, as shown by fluorescent-tagged antisense. A sm-nlar approach was taken by Tomlta et al," who prepared three angiotensmogen mRNA-directed antisense ohgonucleotides and delivered them m hposomes and Sendal virus by direct mJectlon mto the hepatlc portal vem They also noted a decrease m blood pressure m SHR While these results have been encouraging for the use of antisense as a poFrom the Department of Physiology, College of Medicine, Unlversity of Florlda, Gamesvllle, Fla, and Harvard Medical School (P W ), Boston, Mass
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Correspondence to Dr M I Pixlhps, Department of Physiology, College of Medicine, Utuverslty of Flonda, Gamesvllle, FL 32610 E-mad MIP@phys med ufl edu 0 1997 American Heart Assoclatron, Inc tential treatment of hypertension, the maximum effectlveness of a single injection lasts for 7 days. Although this 1s Impressively longer than the response to a single dose of any antlhypertenslve drug currently available, it 1s our hope that we can extend the effectiveness of the antisense approach by delivering antisense m a viral vector that will produce a prolonged reduction m blood pressure for weeks or months There are several vu-al vectors to choose from, mcludmg retrovlruses, adenovlrus, herpes virus, polo virus, and AAV All have disadvantages and some advantages, but the AAV offers the most attractive advantages and the fewest disadvantages AAV 1s safe to use It does not induce any pathogenic response and does not replicate mslde cells The AAV 1s a defective parvovlrus and cannot replicate m cells without the presence of wild-type adenovlrus 73 The AAV IS effective as a vector because it either mtegrates mto the genome or remains m the nucleus as a stable episome 9 rAAV does not produce viral proteins that stimulate inflammatory reactlon, and the vector contains sufficient carrying capacity for the msertlon of an antisense cDNA for AT,-R In this study, we report the results of using AAV vectors that we constructed to deliver AT,-R mRNA antlsense (pAAV-AS and rAAV-AS) The ObJectives of the present study were (1) to demonstrate m vitro the effectiveness of the pAAV-AS stably transfected into NG108-15 cells that express AT,-Rs; (2) to study the effect of pAAV-AS on Ang receptor (ATI and AT;?) bmdmg and to test for speclficlty and efficacy; (3) to demonstrate the expression of the viral vector m brain tissue using the reporter gene lucZ, and (4) to study m vlvo the effect on blood pressure 
Methods

Construction of Plasmid AAV
The AAV-derived vector can be adapted for several genes and promoters between the ITRs at each end (Fig 1) The AAV genome 1s removed, leavmg only the ITRs The vector has a 4 7-kb carrying capacity Foreign genes, such as antlsense DNA and marker genes, can be inserted together with foreign promoters. The plasmid AAV with the (&) gene was designed by Zolotukhm et allo (provided by N Muzyczka) and designated pAAV-gfp The plasmld has a CMV promoter-driven &ip gene and also contains a neomycin (ammoglycoside phosphotransferase) gene, neo', driven by a thynudme kmase promoter, for selection by geneticin (G418) m transduced cells For the antisense vector, a 749-bp fragment (-183 to 566) of rat vascular AT,-R cDNA (provided by T J Murphy m the pKSCal8b plasmld)~~ was amplified with PCR and ligated to pAAV vector m the antisense orlentatlon m place of Rfl, and designated pAAV-AS Recombinant Viruses (Rg 2) were produced using pAAV-AS and pAAV-Rfp Method to Prepare Recombinant AAV To prepare recombinant AAV, Human Embryonic Kidney (HEK293) cells were hansfected with plasmid vector contammg Ang receptor antisense and AAV terminal repeats (pAAV-AS), together with helper plasmtd-deltvenng rep and cnp genes (necessary for AAV lephcatlon) m tram usmg the calcmm phosphate method Eight hours after transfection, adenovlrus was added at a multlphclty of mfection of 5 When cells developed cytopathlc effects (usually after 2 to 3 days), they were harvested m media and centrifuged at 900g at 4°C for 15 minutes Pellet was resuspended m 50 mmol/L Tris/Cl (pH 8 4) and 150 mmol/L NaCl and frozen-thawed three times Cell debris was removed by centrlfugatlon at 2OOOg at 4°C for 10 mmutes, and supernatant was subjected to heating at 56°C for 30 mmutes to mactlvate adenovirus After coohng, preclpltate was separated at 3700g at 4°C for 10 minutes CaCl, (25 mmol/L) was added to supernatant and incubated at 4°C for 1 hour After spinning at 15 300g at 4°C for 20 minutes, the supernatant was removed and equal volume of ammomum sulfate (pH 7 0) saturated at 4"C, was added dropwlse and incubated on ice for 30 minutes The solution was centrifuged at 20 000 rpm m an SW28 rotor at 4°C for 30 minutes The floatmg pellet was dissolved m HEPES-buffered sahne and purified through 1 39 g/cm3 CsCl gradient with 1.5 g/cm' CsCl cushion
The gradient was fractionated, and ahquots were hybridized with [32P]dCTP-labeled random primed AAV probe Positive fractions were pooled and concentrated using Virus Titer Assay Titer of the virus was assayed by dot-blot analysis. Two samples of 2 PL of virus each were diluted m 200 PL of DMEM One sample was digested with 10 U of DNase I at 37°C for 30 minutes, the second sample served as a control The above samples were diluted 1 I with 20 mmol/L Trls/Cl (pH 8 0), 20 mmol/L EDTA (pH 8 0), 1% SDS, and dtgested with 200 ,ug of protemase K at 37°C for 1 horn Samples were phenol/chloroform extracted and ethanol precipitated with ad&on of 40 pg glycogen as the caruer Precipitates were dissolved m 0 4 mol/L NaOH, 10 mmoliL EDTA (pH 8 0), and loaded on the Zeta-probe membrane together with AAV DNA standards Membrane was prehybridized m 7% SDS, 0 25 mol/L sodium phosphate buffer (pH 7 l), 1 mmol/L EDTA (pH 8 0) at 65°C for 10 minutes and then hybridized with
[32P]dCTP-labeled random primed AAV probe at 65°C overnight Membrane was washed m I % SDS, 40 mmol/L sodmm phosphate buffer (pH 7 l), and 1 mmol/L EDTA and autorachographed The intensity of the DNase-digested samples was compared with standards, and virus titer was calculated based on the equation I ng DNA=lXlO'* DNA bases=2X 10" copies of 5-kb ssDNA and on the fact that mfectious vimses are 1% of the total vnus particles Cell Culture
Mouse neuroblastomaXrat ghoma hybnd cells (NG108-15) were grown m DMEM with L-glutamine and 4 5 g/L glucose) supplemented with 10% fetal bovine serum, 100 pmol/L hypoxanthme, 0 4 PmollL ammoptenn, 16 pmol/L thymldme, 100 U/mL pemcllhn, and 100 PglmL streptomycin m an incubator (Quene Systems, Inc) with hutmdlfied atmosphere of 5% CO? and 95% air at 37°C Cells wele used between passages 35 and 50 The medium was replaced every day except the day lmmedlately followmg subcultivation, when It was not changed Transfection of NGlOS-15 Cells by the pAAV-AS NG108-15 cells were plated (day 1) m six-well plates and transfected the followmg day (day 2) at a confluence of ~75% Plastmd (2 pg) and 10 IJL hpofectamme (2 mg/mL) were added to 100 PL Opti-MEM each The two solutions were gently mlxed and kept for 30 minutes at room temperature The mixture was then filled up to 1 mL with Optl-MEM, gently mixed, and added to cells previously washed with Opt]-MEM Cells were placed mto the incubator After 5 hours, the normal me&urn (heat-mactivated fetal bovine serum) was given to the cells On day 3, the cells were subcultivated and pAAV-AS-transfected cells were selected for G418 (600 PgImL) resistance This concentration of G418 IS reqmred to kill 100% of nontransfected To confirm that the transfected cells expressed pAAV-AS, RNA and DNA from NG108-15 cells transfected with pAAV-AS after 2 weeks on G418 selection were isolated by the method of Chomczynslu 12 Control consisted of cells treated with hpofectamme only during transfectlon One hundred nanograms of DNA was analyzed by PCR Presence of neomycin resistance gene was detected usmg a set of primers yielding a 757-bp fragment, the 5' pnmer was 5'-GGA'ITGCACGCAGGTTCTCCG-3' and a 3' pnmer was 5'-CGATAGAAGGCGATGCGCTGC-3' 13 Amphficatlon was performed for 40 cycles with annealing at 65°C As a positive control, 1 pg of the plasmid-contammg neomycin resistance gene was amplified RNA (2 5 ,& was subjected to RT-PCR using SuperScript II Reverse Transcrlptase (Gibco BRL) Two mlcrohters from the RT reaction was added to 100 PL final volume of the PCR reaction, and amplification was performed as described above Amphficatlon products were analyzed on 1% agarose gel stained with ethichum bromide '2JI-[Sar',Iles]Ang II Binding to NGlOS-15 Membranes Membrane Preparation Confluent NG108-15 cells were washed twice with ice-cold phosphate-buffered salme, then dislodged and homogenized (Potter-ElvehJem homogenizer) m ice-cold Tns-HCl buffer (50 mmol/L Tris, 5 mmol/L EDTA, 150 mmol/L NaCl) and centnfuged at 515OOg for 30 minutes at 4°C The pellet was resuspended m the same buffer and homogenized agam The protein content was diluted to 1 mg/mL, and the membranes were used lmmechately for experiments
Binding Assay
One hundred micrograms of membrane proteins were mcubated with 0 2 nmol/L of the radiolabeled Ang IL antagonist '251-[Sar',Ile8]Ang II m the absence and presence of 1 pmol/L cold Ang II, PD123319, or losartan to determine the total, nonspecific AT, and ATI receptor bmchng, respectively The membrane proteins were incubated m triplicate with the receptor hgands m 500 PL Tns-HCl buffer contammg 0 1% bacltracm, 10 pmol/L o-phenanthrolme, and 0 1% BSA for 90 mmutes at room temperature At the end of the incubation procedure, membranebound hgand was collected on Whatman GF/B filter paper using a Brandel cell harvester (Biomedical Research and Development Laboratories, Inc) and the radioactivity was determined with a Beckman y-counter An AT,-R saturation assay using a range of 0 01 to 10 nmol/L '251-[Sar',Ile8] Ang II performed on control, nontransfected cells revealed Kd=l 0 nmol/L and B,,,=21 8 fmol/mg protein (based on two experiments done m tnphcate) For the bmclmg experiment, 0 2 nmol/L lodmated hgand was used, based on the saturation curve Protein Determination Protein content was measured by the method of Bradford using BSA as a standard 14 Animals Adult (weight, 250 to 275 g) and young male (weight, 55 g, 3-week-old) SHR were purchased from Harlan (Indlanapohs, Ind) The rats were kept m cages m a 12 hour light-dark cycle They were fed standard laboratory rat chow and tap water ad hbitum Blood Pressure Measurement SBP was measured with an electrosphygmomanometer (Narco &o-Systems, dlvlsion of International Biomedical, Inc) using the mchrect tail-cuff method Unanesthetlzed rats were placed m a plastic holder that was mounted on a heating strip that was thermostatlcally controlled to mamtam 37°C during measurement Ten readings per rat were taken and the SBPs calculated The adult rats were recorded for 1 month (n=7 experimental animals and 7 controls) After 1 month, SBP measurements were contmued with four experimental rats Delivery of Antisense in Rats ZCV Injection
The adult rats were anesthetized with pentobarbital (65 mg/kg IP) and placed m a stereotactic instrument After removal of scalp skin and cleaning of the exposed dorsal cramum, a hole was refined on the coordmates of -1 mm posterior to the bregma and -1 2 mm lateral to the bregma A Hamilton syringe with a fine needle (33 gauge) was lowered 5 mm mto the brain, and m the experimental group (n=7),5 PL of rAAV-AS viral vector (2X 10' infectious particles/ml) was inJected into the lateral ventricles In the control group (n=7), mock rAAV (5 pL) was inJected in the same way "Mock" Virus was AAV contammg gfi, m place of antisense DNA In all other respects, the construct was the same as the rAAV-AS
The needle was removed and the hole sealed by bone wax Skm Aapv were sutured, and the animal\ were returned to their cages for recovery Blood pressure was recorded 1 week before mJect]on and then at weekly Intervals after the mJection of rAAV-AS
Systemic Injection
For the mtracarchac mJectlons m the young rats, blood pressures were measured from 3 weeks of age The young SHR were divided into two groups For the rAAV-AS cardiac mJectlon (n=6), each animal was anesthetized with methoxyflurane (metafane), and the mjection was made by passmg a needle below the sternum at a slight angle dorsally and laterally to the left side of the animal A pulse felt through the needle indicated that the mJection site was m the heart rAAV-AS 25 PL (2X lo9 mfectlous particles/ml) was injected into the heart In one rat, the inJection faded to enter the heart This rat was monitored by SBP recordmgs with the other groups but was not included m the final analysis Control rats (n=5) received mtracarchac mJection of vehicle (0 9% saline) Losartan mJections were made m a separate group of 4-weekold SHR (n=5) Each animal received a dorsal subcutaneous mJection of losartan 10 mg/kg The mJections were given every 2 days for 2 weeks
Expression of rAAV-1acZ Vector In Vivo
To test the duration of the vector m the brain tissue, rAAVZucZl5 was injected into the lateral ventricles of Sprague-Dawley rats Animals were killed 3 days, 1 week, or 1 month after mJection The hearts were perfused with saline and the brains removed and frozen Sectlons were cut on a Microtome Cryostat (International Equipment Company) (30 Km) and incubated with 5-bromo-4-chloro-3-mdolyl-P-galactoside (x-gal) solution The presence of fl-galactosldase indicated by blue stammg was observed directly by light microscopy Statistical Analysis Data were analyzed with the use of standard statistical methods Repeated blood pressure measurements were taken after gene delivery, and animals were compared with controls with their baseline measurements ANOVA and Neumann-Keuls tests were applied Group data are expressed as mean+SEM Sigmfi- The GFP is seen in more than 50% of the cells.
came was set at the P<.O5 value. All experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Florida.
Results
Expression of GFP in Cultured Cells
The first test was to assess transfection efficiency of pAAV&p in different cell lines. These included ATOO (mouse pituitary cells) and L929 (mouse fibroblasts). Expression of GFP in the cells was measured 24 hours after transfection by comparing green fluorescence of the transfected cells to cells treated only with lipofectamine. 
Detection of the Neomycin Resistance Gene in Transfected NGlOS-15 Cells by PCR and RT-PCR
Presence of the neomycin resistance gene in host DNA was confirmed by PCR of DNA extracted from NGl OS-15 cells transfected with pAAV-AS, 2 weeks after the experiment (Fig 3) . A 757-bp fragment was also detected in RNA extract of pAAV-AS-transfected cells after RT-PCR was performed (Fig 3) . No visible band was present in control cells.
Effect of pAAV-AS Transfection on Ang II Receptor Binding in NGlOS-15 Cells
The pAAV-AS plasmid-transfected NG108-15 cells showed 41% reduction in ATr-R number assayed at 0.2 nmol/L '251-[Sar1,11e8] Ang II compared with the nontransfected cells (1.9t0.3 fmol/mg versus 3.220.6 fmol/mg; n=S; P<.OOl). The AT2-R number was not changed. Fig  4 shows the significant reduction in AT,-R number determined at 3 to 5 weeks after transfection (four consecutive passages).
Expression of rAAV-1acZ Vector In Vivo After Gene Delivery
Fig 5 shows the presence of P-galactosidase in the paraventricular nucleus and supraoptic nucleus 1 month after injection of rAAV-1acZ in adult SHR. Many labeled cells were found spread over other tissues including cortex, amygdala, piriform cortex, and periventricular sites.
Hypotensive Effect of ICV rAAV-AS Gene Delivery in Adult SHR
The effect of rAAV-AS delivered by a single injection (5 pL) in the lateral cerebral ventricles of adult SHR was monitored weekly for 9 weeks. The results show that compared with the baseline levels (181 mm Hg), the treated rats had a significant reduction in blood pressure (231-2 mm Hg; P<.OS) 1 week later (Fig 6) . A persistent reduction in blood pressure continued to be maintained for up to 9 weeks. The controls were tested weekly for 4 weeks. Their blood pressures showed no reduction from baseline, and over the 4-week period, the hypertension was well established.
Compared with the mock vector control rats, there were significant differences at all times for all 4 weeks tested (P<.O5). The original protocol was to test the animals for 1 month, and the control animals were killed after 1 month, but because 66.6% of the experimental group had maintained significantly lower blood pressure than their baseline or control levels, they were recorded for an additional 5 weeks. At 9 weeks, the blood pressure still had not reached the original baseline of the treated group. No effect on heart rate due to the vector was observed. The animals did not appear unhealthy and had no reduction in body weight.
Hypotensive Effect of Intracardiac rAAV-AS Gene Delivery in Young SHR
Intracardiac injection of rAAV-AS at the dose used (25 pL; 2x10" infectious particles/ml) slowed the development of hypertension in young SHR (Fig 7) . We compared the effects of the rAAV vector-carrying antisense with a nontreated control. The SBP of the rAAV-AS animals was significantly below the level of the control animals for 5 weeks after the rAAV-AS injection (P<.Ol). Losartan given to a separate group of SHR by subcutaneous injections every 2 days for 2 weeks also lowered blood pressure compared with untreated controls (Pc.05) (Fig 8) . However, the effect of rAAV-AS lasted longer with a single injection than the losartan-treated group with multiple injections.
Discussion
The results show that gene delivery with a recombinant AAV vector of an antisense DNA to the ATI-R has potential for chronically reducing hypertension in adult animals and slowing the development of hypertension in young animals. Decreased blood pressure was sustained and persisted for over 2 months in the adult SHR, and hypertension development was slowed in young SHR. These A group (n=7) of adult SHR rats (0) is compared with the a control group of age-matched SHR injected with rAAV mock (0) vector (containing GFP and no antisense DNA). In this control group, the hypertension is well established over a period of 4 weeks, while in the rAAV-AS group, blood pressure significantlydecreasedfrom 181 mm Hg baseline levels and was lower than controls for 4 weeks. A group of 4 vector-treated rats were tested for a further 5 weeks and continued to have reduced blood pressure. The rats (4 weeks old) received losartan 10 mg/kg every 2 days for 2 weeks SBP was measured by tall cuff when SHR were 5 weeks of age Losartan for 2 weeks reduced the development of blood pressure slgnlflcantly from controls (f < 05) and at 1 month (P < 05) findings, while preliminary, suggest the feaslblhty of rAAV-AS for gene therapy of hypertension Obviously, the mtracramal route of mjectlon would be unacceptable for treatment of human hypertension, but the experiment m young rats with intracardiac mJectlons suggests that the rAAV-AS wdl also be effective through systemic dellvery. We are exploring nasal sprays and mtramuscular inJections as alternate routes
Further testing requires not only systenuc routes of delivery, but also higher titers and vector modlficatlon with tissue-speafic promoters The CMV promoter has been shown to stimulate gene expresslon m different parts of the brain for up to 3 months 16 In the present study, AAV with a CMV promoter was effective for at least 1 month At that time, brains were expressing @-galactosldase m several cells, including hypothalamic cells In non-brain tissue, such as blood vessels, more specific promoters need to be tested
The experiments are a development from our previous work usmg antrsense ohgonucleotldes In the first report of the use of antisense ohgonucleotldes to reduce hypertension, I we demonstrated that AT, -R mRNA-dlrected an&sense and anglotensmogen mRNA-targeted antisense when InJected mto SHR were both effective m reducing blood pressure slgmficantly The reduction m blood pressure was simultaneous with a reduction m receptor bindmgJ7 in key regions of the bram that have been associated with cardiovascular regulation In the orlgmal report, the effects on blood pressure were only measured for 24 hours after inJection In a later study, we demonstrated that the effects lasted for up to 7 days with a single admmlstratlon of AS-ODN.2 While the bram offers several advantages from a research point of view for studying the feastblhty of antlsense mhlbltlon, the ultimate goal 1~ to provide a safe, efficient method of delivery for humans Therefore, in subsequent studies we inJected antisense systemlcallyS and demonstrated that anglotensmogen antisense ODN mJetted mtra-arterially in hposome encapsulation was taken up by the hver and reduced the levels of anglotensmogen with simultaneous reduction in blood pressure m SHR A simrlar but more complex study was carried out by Tomlta et al,6 who delivered three antlsense ohgonucleotldes to anglotensmogen via the hepatlc portal vem and also demonstrated a transient decrease m blood pressure These positive results with antisense ollgonucleotldes stimulated us to test vu-al vector delivery to produce longterm hypotenslon with antisense mhlbitlon. We chose to use the AAV because of its many advantages compared with other vectors such as retrovlruses or adenovlrus The properties of AAV vectors include safety, because AAV 1s nonpathogemc and does not replicate It produces no viral genes that stimulate inflammatory responses It has site-specific integration m the genome of chromosome 19.839 It can be concentrated and 1s stable m tissue The vector can easily be modified to carry foreign genes and tissue-specific promoters Therefore, we constructed an rAAV with antisense to AT,-R The m vitro studies mdlcated efficient transfectlon of foreign genes (gfp and lacZ) mto cultured cells. The PCR and RT-PCR detection of neomycin resistance gene confirmed that the pAAV-AS was bemg expressed m the transfected cells There was a decrease m AT,-R number m the NGl08-15 cells m the pAAV-AS-transfected cells It IS not known at this stage whether rAAV integrates mto the genome and 1s expressing AS mRNA or whether the expression IS eplsomal. Further studies with low-molecular-weight DNA18 will resolve this. The rAAV-AS Induced a prolonged decrease m blood pressure for as long as we recorded It m this experiment (2 months). More experiments are needed to confirm the result, but takmg the data from adult and young SHR together, the IAAV-AS does appear to be effective m chronically lowering blood pressure P-Gal gene expression from the rAAV-1ucZ lasted at least 1 month, suggesting that the rAAV-AS was also expressed for this time Kaphtt et a116 and McGowan et al 19 have reported that the rAAV vector with CMV promote1 expresses P-galactosldase m the brain for up to 3 months Therefore, it seems likely that the rAAV-AS was expressing the antisense DNA during the 2-month period In the young rats given rAAV-AS by mtracardlac mJectlon, it IS not known m which tissue the rAAV was sequestered and expressed Further analysis of RT-PCR m multlple tissue samples 1s necessary to determme the fate of the AAV At present, the data suggest that the reduction m blood pressure compared with controls and the retardation of hypertension development over 5 weeks was due to AT,-R decrease The data obtained with the AT,-R antagonist losartan indicate that It 1s the blockade of AT,-Rs that underlies the reduction rn blood pressure The advantage of the rAAV-AS for possible therapy IS that it can be effective when given once rather than repeated for several weeks The experiment 1s bemg repeated with younger SHR to test d there IS a critical period m the development of Angmediated peripheral resistance that, when inhibited, would permanently prevent the development of hypertension Several studies Indicate this IS possible. We showed that levels of Ang II ale elevated m 4-week-old SHR compared with Wlstar-Kyoto rats 2" Harrap et a121 found that ACE mhlbltlon m 6-to lo-week-old SHR prevents hypertension and proposed a critical period spanning those weeks Our data show that the rise m blood pressure m the control rats 1s very rapid m weeks 3,4, and 5 of life By 6 to 10 weeks, hypertension 1s established, so it would seem that the early weeks of age would be more vulnerable to Ang II-receptor changes.
Several recent studies have apphed gene therapy to hypertension since the antisense studies began m 1993 I-3 Lm et a122 showed that human ANP, delivered as a naked DNA construct, fused to the ROW sarcoma virus 3' long-termlnal repeat and injected mtravenously mto SHR through the tall vem, produced decreased blood pressure m 4-weekold SHR that lasted for 7 weeks The maximal reduction m pressure was 21 mm Hg. These results are strikmgly similar to the present results m young SHR usmg quite different gene-modlficatlon procedures one to introduce a gene associated with vasodllatlon and dmresls (ANP) and the other an antisense to mhlbltlon of a vasoconstrlctor (Ang 11). Both approaches raise the feasibility of gene therapy for treatment in human hypertension with safe delivery systems and open new posslblhtles for research
